Biomerica Inc. highlighted its diagnostics and manufacturing operations, including two FDA, CE and CFDA registered manufacturing facilities in California and Mexico, and described its inFoods IBS test, a laboratory test designed to identify patient-specific food triggers associated with IBS symptoms. The company cited clinical data for inFoods IBS, including a randomized double-blind sham-controlled study and a June 2025 publication in Gastroenterology, and noted a $300 Medicare payment rate effective Jan. 1, 2026. Biomerica also outlined commercialization efforts for inFoods IBS, including integration into Gastro Health’s patient systems for ordering, and provided an update on its H. pylori antigen test, stating it has received FDA 510(k) clearance and is targeted primarily to large laboratory customers. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.